Longboard Surfs PACIFIC Waves To Pivotal Phase III Epilepsy Program

 
• By Alaric DeArment

The company’s valuation quadrupled after it announced positive Phase Ib/IIa results for bexicaserin in Dravet syndrome, Lennox-Gastaut syndrome and other epileptic disorders.

Longboard announced results of its Phase Ib/IIa PACIFIC study of bexicaserin in epilepsy, quadrupling its stock price • Source: Shutterstock

More from Clinical Trials

More from R&D